ES2288470T3 - Factor de crecimiento similar a la insulina que une la proteasa de la proteina-4. - Google Patents

Factor de crecimiento similar a la insulina que une la proteasa de la proteina-4. Download PDF

Info

Publication number
ES2288470T3
ES2288470T3 ES00914965T ES00914965T ES2288470T3 ES 2288470 T3 ES2288470 T3 ES 2288470T3 ES 00914965 T ES00914965 T ES 00914965T ES 00914965 T ES00914965 T ES 00914965T ES 2288470 T3 ES2288470 T3 ES 2288470T3
Authority
ES
Spain
Prior art keywords
papp
baselineskip
igfbp
prombp
protease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES00914965T
Other languages
English (en)
Spanish (es)
Inventor
Michael Toft Overgaard
Claus Oxvig
Cheryl A. Conover
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mayo Foundation for Medical Education and Research
Mayo Clinic in Florida
Original Assignee
Mayo Foundation for Medical Education and Research
Mayo Clinic in Florida
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mayo Foundation for Medical Education and Research, Mayo Clinic in Florida filed Critical Mayo Foundation for Medical Education and Research
Application granted granted Critical
Publication of ES2288470T3 publication Critical patent/ES2288470T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/48Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6489Metalloendopeptidases (3.4.24)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/37Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/689Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to pregnancy or the gonads
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
ES00914965T 1999-03-15 2000-03-15 Factor de crecimiento similar a la insulina que une la proteasa de la proteina-4. Expired - Lifetime ES2288470T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12454199P 1999-03-15 1999-03-15
US124541P 1999-03-15

Publications (1)

Publication Number Publication Date
ES2288470T3 true ES2288470T3 (es) 2008-01-16

Family

ID=22415480

Family Applications (1)

Application Number Title Priority Date Filing Date
ES00914965T Expired - Lifetime ES2288470T3 (es) 1999-03-15 2000-03-15 Factor de crecimiento similar a la insulina que une la proteasa de la proteina-4.

Country Status (10)

Country Link
US (2) US20060148018A1 (de)
EP (1) EP1169058B1 (de)
JP (1) JP2002538804A (de)
AT (1) ATE361756T1 (de)
AU (3) AU783035B2 (de)
CA (1) CA2367360C (de)
DE (1) DE60034779T2 (de)
DK (1) DK1169058T3 (de)
ES (1) ES2288470T3 (de)
WO (1) WO2000054806A1 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7115382B1 (en) 1999-03-15 2006-10-03 Mayo Foundation For Medical Education And Research Method for detecting IGFBP-4 protease without detecting IGFBP-4 protease/proMBP Complex
CA2464121C (en) 2000-10-20 2013-08-13 Como Biotech Aps Pregnancy-associated plasma protein-a2 (papp-a2)
US6436629B1 (en) * 2000-10-27 2002-08-20 The Regents Of The University Of California Modulating angiogenesis
US6500630B2 (en) 2001-01-12 2002-12-31 Mayo Foundation For Medical Education And Research Marker for inflammatory conditions
ES2314624T3 (es) 2004-01-28 2009-03-16 Turun Yliopisto Metodo mejorado para el diagnostico del sindrome coronario agudo.
WO2005087805A1 (en) * 2004-03-05 2005-09-22 Regenerx Biopharmaceuticals, Inc. Treating or preventing extracellular matrix build-up
GB0910751D0 (en) 2009-06-23 2009-08-05 Procure Therapeutics Ltd Prostate cancer vaccine
FI20095733A0 (fi) * 2009-06-29 2009-06-29 Hytest Oy IGFBP-4-fragmenttien määrittäminen diagnostisena menetelmänä
GB201016864D0 (en) * 2010-10-06 2010-11-17 Univ Aston Therapeutic methods
EP3660168A4 (de) * 2017-07-26 2021-04-21 Sekisui Medical Co., Ltd. Verfahren zum nachweis mutanter gene
JP2025539937A (ja) 2022-11-15 2025-12-10 カリコ ライフ サイエンシーズ エルエルシー 抗papp-a抗体及びその使用方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994021686A1 (en) * 1993-03-19 1994-09-29 Northern Sydney Area Health Service Papp-a, its immunodetection and uses
US5876433A (en) * 1996-05-29 1999-03-02 Ethicon, Inc. Stent and method of varying amounts of heparin coated thereon to control treatment
DE19757250A1 (de) * 1997-12-22 1999-07-01 Forssmann Wolf Georg Prof Dr Insulin-like growth factor binding protein und seine Verwendung

Also Published As

Publication number Publication date
AU783035B2 (en) 2005-09-15
AU2009200138A1 (en) 2009-02-12
EP1169058A1 (de) 2002-01-09
US20090191640A1 (en) 2009-07-30
CA2367360A1 (en) 2000-09-21
AU3627800A (en) 2000-10-04
EP1169058B1 (de) 2007-05-09
CA2367360C (en) 2011-08-09
DK1169058T3 (da) 2007-09-10
DE60034779D1 (de) 2007-06-21
US20060148018A1 (en) 2006-07-06
JP2002538804A (ja) 2002-11-19
EP1169058A4 (de) 2002-07-17
DE60034779T2 (de) 2008-01-17
AU2005244559A1 (en) 2006-01-19
AU2005244559B2 (en) 2008-11-27
WO2000054806A1 (en) 2000-09-21
AU2009200138B2 (en) 2012-10-11
ATE361756T1 (de) 2007-06-15

Similar Documents

Publication Publication Date Title
AU2009200138B2 (en) Use of insulin-like growth binding protein-4 protease
JP5072950B2 (ja) 妊娠関連血漿蛋白−a2(papp−a2)
US8263071B2 (en) Protein involved in ovarian cancer
Didierjean et al. Localization and characterization of the interleukin 1 immunoreactive pool (IL-1 alpha and beta forms) in normal human epidermis
JP2005501549A (ja) 癌腫の診断
US6379671B1 (en) Reagents and methods useful for detecting diseases of the breast
EP1451552B1 (de) Zum nachweisen von erkrankungen der brust geeignete reagenzien und verfahren
US7115382B1 (en) Method for detecting IGFBP-4 protease without detecting IGFBP-4 protease/proMBP Complex
WO2014180485A2 (en) Pappalysin regulator
US20060147478A1 (en) Protein involved in carcinoma
US20070142276A1 (en) Protein involved in carcinoma
US6552164B1 (en) Reagents and methods useful for detecting diseases of the breast
ES2326324T3 (es) Me-5, me-2 y epp2: antigenos de proteina humana reactivos con anticuerpos presentes en el suero de mujeres que padecen de endometriosis.
WO2005023300A2 (en) Method for treating, preventing and/or diagnosing cancer, related to the use of mal2 polypeptide
JP2012013504A (ja) 子宮体部類内膜腺癌の予後判定方法
WO2005019257A1 (en) A protein involved in pancreatic cancer